Table 1 Socio-demographic, clinical and laboratory characteristics of patient population collected before initiating benralizumab treatment
Characteristics at index date | Evaluable population (N = 162) |
|---|---|
Age (years) | 56.0 ± 12.7 |
Females | 99 (61.1) |
BMI (kg/m2) | |
Underweight/normal weight Overweight Obese Unknown | 58 (35.8) 62 (38.3) 26 (16.0) 16 (9.9) |
Smoking status | |
Current smokers Past smokers | 5 (3.1) 44 (27.2) |
Asthma duration (years) (N = 161) | 13.5 (8.1–25.4) |
SEA duration (years) (N = 158) | 1.8 (1.0–4.3) |
Patients positive to ≥ 1 (perennial and/or seasonal) allergen | 77 (47.5) |
BEC (cells /mm3) Total serum IgE (IU/mL) | 600 (430–890) 215 (83–520) |
Comorbidities | 141 (87.0) |
≥ 1 current asthma-related condition Nasal polyposis, current or past Chronic rhinosinusitis without nasal polyposis ≥ 1 current OCS-related condition (osteoporosis, type 2 diabetes etc.) ≥ 1 other ongoing comorbidities | 91 (56.2) 86 (53.1) 43 (26.5) 64 (39.5) 38 (23.5) |
OCS for asthma treatment OCS daily (prednisone equivalent) dose (mg) (N = 39) | 41 (25.3) 10 (5–25) |
Exacerbations during the 12 months prior to index date (N = 154) | |
Patients with ≥ 1 exacerbation of any severity Patients with ≥ 1 severe exacerbation | 144 (93.5) 57 (37.0) |
AER, any | 4.10 |
AER, severe | 0.98 |
Lung function | |
Pre-BD FEV1 (L) (N = 121) Post-BD FEV1 (L) (N = 80) Pre-BD FEV1 predicted (%) (N = 125) Post-BD FEV1 predicted (%) (N = 79) Pre-BD FVC (N = 116) Post-BD FVC (N = 75) FeNO (ppb) (N = 52) | 1.9 (1.4–2.5) 2.0 (1.4–2.8) 71.0 (54.0–84.0) 73.0 (59.0–93.0) 2.8 (2.3–3.5) 3.0 (2.3–3.9) 42.0 (23.0–66.0) |
ACT score (N = 120) | 14 (12–17.5) |
Patients previously treated with biologics | 38 (23.5) |
Healthcare resource utilization for asthma per patient (N = 150) | |
Primary care physician/GP office visits Specialist visits ED admissions Hospitalizations | 1.1 ± 1.8 2.4 ± 2.5 0.1 ± 0.4 0.2 ± 0.5 |